Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Toronto

$24,250.00

High-throughput screening of nanoparticle tissue penetration using a microfluidic device.

FY 2013-14

Summary
The proposed project involves a new collaboration between the Dr. Rocheleau and cYtodiagnostics(http://www.cytodiagnostics.com/). cYtodiagnostics specializes in the production and development of gold and silver nanoparticles, secondary antibodies and magnetic nanoparticles. They would like to expand their products for in vivo targeting; however, they lack the resources to invest directly in this approach. Dr. Rocheleau has developed a microfluidic device to deliver nanoparticles to ex vivo tissue in a controlled flow environment. There has been significant effort in the last 15 years in developing nanotechnology for cancer applications. A current concept in cancer nanotechnology research is the determination of the size and shape on cellular uptake and transport, since these physical parameters have significant impact on therapeutic responses and diagnostic sensitivity. In contrast, we would like to screen nanoparticle interaction with pancreatic islets. While researchers have used cancer models for evaluating the influence of nanoparticle design in mediating therapeutic responses and diagnostic sensitivity, this has not been done use cell or tissue models that arerelevant to diabetes. By characterizing the influence of nanoparticle parameters on pancreatic islet, our data would be relevant to the engineering of nanosystems for diabetes applications.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
454253-2013
Name nom
Rocheleau, Jonathan
Department département
Biomaterials and Biomedical Engineering, Inst. of (IBBME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
24250
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
High-throughput screening of nanoparticle tissue penetration using a microfluidic device.
Keyword
NSERC
Application summary
The proposed project involves a new collaboration between the Dr. Rocheleau and cYtodiagnostics(http://www.cytodiagnostics.com/). cYtodiagnostics specializes in the production and development of gold and silver nanoparticles, secondary antibodies and magnetic nanoparticles. They would like to expand their products for in vivo targeting; however, they lack the resources to invest directly in this approach. Dr. Rocheleau has developed a microfluidic device to deliver nanoparticles to ex vivo tissue in a controlled flow environment. There has been significant effort in the last 15 years in developing nanotechnology for cancer applications. A current concept in cancer nanotechnology research is the determination of the size and shape on cellular uptake and transport, since these physical parameters have significant impact on therapeutic responses and diagnostic sensitivity. In contrast, we would like to screen nanoparticle interaction with pancreatic islets. While researchers have used cancer models for evaluating the influence of nanoparticle design in mediating therapeutic responses and diagnostic sensitivity, this has not been done use cell or tissue models that arerelevant to diabetes. By characterizing the influence of nanoparticle parameters on pancreatic islet, our data would be relevant to the engineering of nanosystems for diabetes applications.